Login to Your Account



NEJM Study: Truvada Cut HIV Risk by 44%

Gilead Seeking FDA Nod for Tibotec-Partnered HIV Combo

By Donna Young


Wednesday, November 24, 2010
WASHINGTON – On the same day that Gilead Sciences Inc. revealed it had submitted a new drug application to the FDA to market a single combination pill of Truvada (emtricitabine and tenofovir disoproxil fumarate) plus Tibotec Pharmaceuticals Ltd.'s TMC278 (rilpivirine hydrochloride) as a treatment for HIV-1 infection in adults, researchers reported results showing that a daily pre-exposure prophylactic (PrEP) dose of Truvada cut the risk of HIV infection by 44 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription